SCHEMBL20122989

SCHEMBL20122989

COc1cc(-c2cc(Cl)cc3c2[nH]c2c(C)nccc23)ccc1OCc1cccc(F)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.38
SYK P43405 6/20 0.35
EGFR P00533 1/20 0.35
KIT P10721 3/20 0.34
DYRK1A Q13627 2/20 0.34
LCK P06239 1/20 0.34
BTK Q06187 1/20 0.34
CCNB2 O95067 2/20 0.33
CDK1 P06493 2/20 0.33
CCNB1 P14635 2/20 0.33
CCNA2 P20248 2/20 0.33
CDK2 P24941 2/20 0.33
CCNA1 P78396 2/20 0.33
CDK5 Q00535 2/20 0.33
CDK5R1 Q15078 2/20 0.33
CCNB3 Q8WWL7 2/20 0.33
KDM4E B2RXH2 1/20 0.33
DYRK3 O43781 1/20 0.33
CCNT1 O60563 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664318 1.00 MAOA (0.38) MAOASYKEGFRKITDYRK1A
SCHEMBL20123052 0.89 MAOA (0.50) MAOASYKEGFRCYP1A2CYP3A4
SCHEMBL30664245 0.89 MAOA (0.50) MAOASYKEGFRCYP1A2CYP3A4
SCHEMBL30664215 0.87 MAOA (0.46) MAOADYRK1ACCNB2CDK1CCNB1
SCHEMBL20123027 0.87 MAOA (0.46) MAOADYRK1ACCNB2CDK1CCNB1
SCHEMBL30664326 0.84 MAOA (0.48) MAOADYRK1AKDM4EALDH1A1CYP1A2
SCHEMBL20122860 0.84 MAOA (0.48) MAOADYRK1AKDM4EALDH1A1CYP1A2
SCHEMBL20122812 0.83 KIT (0.45) MAOAKITDYRK1ACCNB2CDK1
SCHEMBL30664149 0.83 KIT (0.45) MAOAKITDYRK1ACCNB2CDK1
SCHEMBL20123016 0.81 MAOA (0.48) MAOADYRK1AKDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 MAOA 245/4885SYK 3620/4885EGFR 449/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 MAOA 245/4885SYK 3620/4885EGFR 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.